Assessment of multifunctional contrast agent probes in neuroimaging: Implications of nanopharmaceutical therapeutic interventions

Journal of Advanced Pharmaceutical Technology and Research

Volumn 4, Issue 3, 2013, Pages 128-133

  MacHtoub, Lina ^a,b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b Univklinik Radiodiagnostik   (Austria)

Author keywords

Central nervous system; nanoparticles neurological disorders; oxides

Indexed keywords

ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN TISSUE; CONTROLLED STUDY; DEGENERATIVE DISEASE; EARLY DIAGNOSIS; INFLAMMATION; MICROSCOPY; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHANTOM; PHOTOACOUSTICS; PRIORITY JOURNAL; RAT; REVIEW;

EID: 84883734678     PISSN: 22314040     EISSN: 09762094     Source Type: Journal    
DOI: 10.4103/2231-4040.116777     Document Type: Review

References (31)

1. Tam AC. Application of Photoacoustic Sensing Techniques, Rev Mod Phys 1986;58:381-431.
2. Bell AG. On the Production and Reproduction of Speech by Light. Am J Sci 1980;20:305-24.
3. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultra small superparamagnetic iron oxide: Characterization of a new class of contrast agents for MRimaging. Radiology 1990;175:489-93.
4. Sosnovik DE, Caravan P. Molecular MRI of Atherosclerotic Plaque With Targeted Contrast Agents. Curr Cardiovasc Imaging Rep 2009;2:87-94.
5. Gupta AK, Gupta M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 2005;26:1565-73.
6. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004;17:484-99.
7. Kelly KA, Nahrendorf M, Yu AM, Reynolds F, Weissleder R. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Biol 2006;8:201-7.
8. Batavelji-D, Djogo N, Zupunski L, Baji-A, Nicaise C, Pochet R, et al. Live monitoring of brain damage in the rat model of amyotrophic lateral sclerosis. Gen Physiol Biophys 2009;28 Spec No: 212-8.
9. Andjus PR, Batavelji-D, Vanhoutte G, Mitrecic D, Pizzolante F, Djogo N, et al. In vivo morphological changes in animal models of amyotrophic lateral sclerosis and Alzheimer's-like disease: MRI approach. Anat Rec (Hoboken) 2009;292:1882-92.
10. Machtoub L, Batavelji-D, Andjus PR. Molecular imaging o brain lipid environment of lymphocytes in amyotrophic lateral sclerosis using magnetic resonance imaging and SECARS microscopy. Physiol Res 2011;60 Suppl 1:S121-7.
11. Machtoub LH. Investigating neurodegenerative disorder systems using USPIO nanoparticles with (SECARS) microscopy. J Neurol 2010;257:S65-8.
12. Michalska M, Machtoub L, Manthey HD, Bauer E, Herold V, Krohne G, et al. Visualization of vascular inflammation in the atherosclerotic mouse by ultrasmall superparamagnetic iron oxide vascular cell adhesion molecule-1-specific nanoparticles. Arterioscler Thromb Vasc Biol 2012;32:2350-7.
13. Machtoub LH. Monitoring the inflammatory process by surface enhanced nanoimaging microscopy. Curr Neurovasc Res 2012;9:214-21.
14. Baraczka K, Nékám K, Pozsonyi T, Jakab L, Szongoth M, Seszták M. Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1and sL-selectin) in the cerebro spinal fluid and serum of patients with multiple sclerosis and system ic lupus erythematosus with central nervous involvement. Neuroimmuno modulation 2001;9:49-54.
15. Fabry Z, Waldschmidt MM, Hendrickson D, Keiner J, Love-Homan L, Takei F, et al. Adhesion molecules on murine brain microvascular endothelialcells: Expression and regulation of ICAM-1and Lgp55. J Neuroimmunol 1992;36:1-11.
16. Ke Y, Ho K, Du J, Zhu L, Xu Y, Wang Q, et al. Role of soluble ceruloplasmin in iron uptake by midbrain and hippocampus neurons. J Cell Biochem 2006;98:912-9.
17. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+T cells support glial neuroprotection, slow disease progression, and modify glial morphology in ananimal model of inherited ALS. Proc Natl Acad Sci USA 2008;105:15558-63.
18. Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol1998;44:819- 24.
19. Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 2002;52:448-57.
20. Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. In: Quinn PJ, Wang X, editors. Lipids in Health and Disease. Vol. 49 NewYork: Springer-Verla; 2008. p. 241-68.
21. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, et al. Superparamagneticironoxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000;35:460-71.
22. Portet F, Cadilhac C, Touchon J, Camu W. Cognitive impairment in motor neuron disease with bulbar onset. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:23-9.
23. Fabis MJ, Scott GS, Kean RB, Koprowski H, Hooper DC. Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitisin knock out mouse models. Proc Natl Acad Sci USA 2007;104:5656-61.
24. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020-34.
25. Elovaara I, Ukkonen M, Leppäkynnäs M, Lehtimäki T, Luomala M, Peltola J, et al. Adhesion molecules in multiple sclerosis: Relation to subtypes of disease and methylprednisolone therapy. Arch Neurol 2000;57:546-51.
26. Peschen M, Lahaye T, Hennig B, Weyl A, Simon JC, Vanscheidt W. Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1andVLA-4 in the skin is modulated in progressing stages of chronic venous in sufficiency. Acta Derm Venereol 1999;79:27-32.
27. Blömer UL, Naldini IM, Verma S. Appications of gene therapy to the CNS. Hum Mol Genet 1996;5:1397-404.
28. Davtyan H, Ghochikyan A, Movsesyan N, Ellefsen B, Petrushina I, Cribbs DH, et al. Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses. Neurodegener Dis 2012;10:261-4.
29. Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998;9:1757-61.
30. D'Angelo B, Santucci S, Benedetti E, DiLoreto S, Phani RA, Falone S, et al. Cerium oxide nanoparticles trigger neuronal survival in a human Alzheimer disease model by modulating BDNF pathway. Curr Nanosci 2009;5:167-76.
31. Suh WH, Suslick KS, Stucky GD, Suh YH. Nanotechnology, nanotoxicology, and neuroscience. Prog Neurobiol 2009;87: 133-70.